Johnson & Johnson (NYSE:JNJ) Stock Position Raised by S.A. Mason LLC

S.A. Mason LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% in the first quarter, Holdings Channel reports. The firm owned 7,420 shares of the company’s stock after buying an additional 117 shares during the period. S.A. Mason LLC’s holdings in Johnson & Johnson were worth $1,174,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Keener Financial Planning LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth about $40,000. WFA Asset Management Corp raised its stake in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $44,000. Disciplined Equity Management Inc. bought a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $45,000. Finally, Grayhawk Investment Strategies Inc. raised its stake in shares of Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after acquiring an additional 259 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 22nd. The Goldman Sachs Group started coverage on Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 20th. Bank of America lowered their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Finally, HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $174.07.

Johnson & Johnson Trading Up 0.3 %

Shares of JNJ traded up $0.38 during trading hours on Thursday, hitting $147.20. 257,102 shares of the stock traded hands, compared to its average volume of 7,350,285. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The firm has a market capitalization of $354.26 billion, a PE ratio of 9.15, a price-to-earnings-growth ratio of 2.45 and a beta of 0.53. The business has a fifty day moving average of $148.13 and a 200-day moving average of $154.24.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the prior year, the firm posted $2.68 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.63 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.37%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.